Smoking was associated with greater odds of EPI, and prevalence ranged from 21.1% to 52.1% depending on the diagnostic test used.
News|Articles|July 6, 2026
4 Gastroenterology Headlines You Missed in June 2026
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
Catch up on phase 3 data for tulisokibart and obefazimod, expert perspective on linaclotide's expanded FDA approval, and more.
Advertisement
Advertisement
June brought continued momentum in
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Advertisement
Advertisement